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Abstract
Background: There is substantial uncertainty regarding the efficacy of antidepressants in the treatment of bipolar
disorders.
Methods: Traditional randomized controlled trials and statistical methods are not designed to discover if, when, and
to whom an intervention should be applied; thus, other methodological approaches are needed that allow for the
practice of personalized, evidence-based medicine with patients with bipolar depression.
Results: Dynamic treatment regimes operationalize clinical decision-making as a sequence of decision rules, one per
stage of clinical intervention, that map patient information to a recommended treatment. Using data from the acute
depression randomized care (RAD) pathway of the Systematic Treatment Enhancement Program for Bipolar Disorder
(STEP-BD) study, we estimate an optimal dynamic treatment regime via Q-learning.
Conclusions: The estimated optimal treatment regime presents some evidence that patients in the RAD pathway of
STEP-BD who experienced a (hypo)manic episode before the depressive episode may do better to forgo adding an
antidepressant to a mandatory mood stabilizer.
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Background
Bipolar disorders are a group of chronic lifelong recur-
rent psychiatric disorders characterized by episodic shifts
in mood, energy, social and vocational functioning, and
activity levels (Phillips and Kupfer 2013). Worldwide,
bipolar disorders are a leading cause of disability (Vos et al.
2013) and associated with a substantial economic burden
on society (Kleine-Budde et al. 2014). Standard antide-
pressant medications have been proved to be effective
for acute and long-term treatment of unipolar depres-
sion (Bauer et al. 2013); however, supporting evidence for
the inclusion of standard antidepressants in the acute and
long-term treatment of bipolar depression is more lim-
ited and controversial (Grunze et al. 2010, Pacchiarotti
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et al. 2013). Furthermore, there is concern that an-
tidepressants can induce abnormal mood elevation (Licht
et al. 2008). We use data from the Systematic Treatment
Enhancement Program for Bipolar Disorder (STEP-BD)
(Sache et al. 2003, 2007) to estimate an optimal dynamic
treatment regime (DTR) (Chakraborty and Murphy 2014;
Murphy 2003, Robins 2004, Schulte et al. 2014), for bipolar
depression. A DTR is a sequence of decision rules, one per
stage of intervention, that map up-to-date patient infor-
mation to a recommended treatment; thus, an estimated
optimal DTR can be used to generate hypotheses about
how patient history and outcomes should dictate treat-
ment selection. The estimated optimal DTR for bipolar
depression constructed from the STEP-BD study suggests
the hypothesis that standard antidepressants should not
be used to supplement mood stabilizers for patients with
a prior hypomanic episode.
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A DTR aims to select if, when, what, and to whom
treatment should be assigned and thereby fits into
the paradigm of personalized medicine. Because DTRs
select treatment according to the uniquely evolving
health status of each patient, they are suited to man-
age chronic illnesses with patient response heterogeneity;
thus, DTRs have tremendous potential for personalizing
and improving treatment strategies for bipolar disorder
(Leboyer and Kupfer 2010; Nierenberg et al. 2013).
Optimal DTRs have been estimated for wide range of
chronic illnesses including major depressive disorder
(Chakraborty et al. 2013; Chakraborty and Moodie 2013),
attention deficit hyperactivity disorder (Laber et al. 2014;
Lei et al. 2012, Nahum-Shani et al. 2012a), schizophre-
nia (Laber et al. 2014; Shortreed et al. 2011), HIV/AIDS
(Moodie et al. 2007; Sterne et al. 2009), and cigarette
addiction (Strecher et al. 2006). Estimation of an optimal
DTR is typically done as a secondary, exploratory analy-
sis and viewed as a method of generating hypotheses for
follow-up confirmatory experiments (Murphy 2005). This
is the perspective we take here; nevertheless, we show that
an estimated optimal DTR appears to perform markedly
better than any fixed treatment strategy.
In the “STEP-BD study” section, we review the STEP-
BD study. In the “Dynamic treatment regimes and
Q-learning” section, we formalize DTRs and introduce
the Q-learning estimation algorithm. In the “Analysis of
STEP-BD” section, we present an analysis of STEP-BD.
Methods
The study on which our analyses are based was approved
by the institutional review board at each study site and
was overseen by a data and safety monitoring board (for
more details, see http://www.ncbi.nlm.nih.gov/pubmed/
17392295).
STEP-BD study
STEP-BD is a long-term study of bipolar disorder funded
by the National Institute of Mental Health (NIMH). Its
aim was “to generate externally valid answers to treat-
ment effectiveness questions related to bipolar disorder”
(Sachs et al. 2003). Patients of age older than 15 years
fulfilling DSM-IV criteria for any subtype of bipolar disor-
ders could enter the study registry. In total, 4,360 patients
from 22 sites in United States enrolled. The study lasted
for 7 years (2001–2007). In STEP-BD, there are two dif-
ferent treatment pathways: standard care pathway (SCP)
and randomized care pathway (RCP). SCP is open to all
participants with a diagnosis of bipolar disorders. Each
treatment delivered is open and will follow treatment
guidelines. Decisions are made on the basis of shared
decision-making. After patients signed informed consent
for entry into the STEP-BD study registry, all patients
enter the SCP. If a patient’s status meets the eligibility
criteria at one of the follow-up visits during the SCP for a
study within the RCP, additional consent is requested for
entry into that RCP. The RCP utilizes methods appropri-
ate for efficacy studies, and random assignment is needed
to provide answers to clinical questions. In the RCP, there
are three different pathways each addressing unmet needs
in the treatment of bipolar disorder: acute depression ran-
domized (RAD) pathway, acute depression psychosocial
intervention (PAD) pathway, and refractory depression
(REFD) pathway. If patients are unwilling to consent to
one of the RCPs, they remain in the SCP. In general, the
decision of pathway (SCP versus RCP) is based on both the
doctor’s and patient’s opinion. In STEP-BD, patients could
switch pathways based on doctor’s or their own prefer-
ence as well as inclusion and exclusion criteria. Figure 1
shows the diagram of STEP-BD study. Our analysis uti-
lizes patients enrolled in RAD.
Acute depression randomized pathway
As mentioned above, the RAD pathway is one of the three
RCPs in STEP-BD. In addition to satisfying the general
entry criteria for STEP-BD study registry, patients had to
be at least 18 years old and fulfill the DSM-IV criteria for
a major depressive episode in the context of bipolar I or
bipolar II disorder. All patients with a history of intoler-
ance or non-response to both bupropion and paroxetine
were excluded, as well as those requiring current short-
term treatment for a coexisting substance-abuse disorder
or requiring the addition of antipsychotic medication or a
change in the dose of a long-term antipsychotic medica-
tion (Sachs et al. 2007). In addition, patients had to take
a mood stabilizer at the time of randomization or agree
to begin treatment with a mood stabilizer. Moreover,
they had to agree to have all non-study antidepressants
Figure 1 STEP-BD Design. There were 4,360 patients who
participated in SCP and 461 patients who participated in RCP. Patients
in SCP satisfying RCP criteria entered RCP. In RCP, there are three
different pathways: RAD, PAD, and REFD. Patients can enter more
than one random pathways.
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tapered after initiation of study drug, with the antide-
pressant discontinued by the end of week 2. The purpose
of RAD was to explore the effectiveness of adjunctive
antidepressant treatment, in addition to a mood stabi-
lizer. Initially, themood stabilizers were limited to lithium,
valproate, the combination of lithium and valproate, or
carbamazepine. However, later on, any FDA-approved
antimanic agent could be used as mood stabilizers. Table 1
shows the percentages of different mood stabilizers used
in RAD. At week 0, patients were randomly assigned to
one antidepressant (150 mg of a sustained release formu-
lation of bupropion or 10 mg of paroxetine to begin with)
or placebo. After 6 weeks, patients with non-response
on the placebo were randomized to either paroxetine or
bupropipon; patients with non-response on the antide-
pressant were assigned to either openly increase the dose
of their current antidepressant or add another antide-
pressant. At weeks 8, 10, or 12, clinicians will make final
decision for patients based on their clinical status col-
lected from clinical monitoring form (CMF). During the
study, patients need to visit their doctors every week to fill
in the CMF (Sachs et al. 2002). Patients were allowed to
switch to SCP (opt out) at any time by their preference or
doctor’s opinion. Patients who had severe adverse effects
or met criteria for hypomania or mania discontinued the
antidepressant or placebo and received open treatment
while remaining in STEP-BD. Since after 6 weeks, only
one patient with non-response on the antidepressant was
assigned to add another antidepressant, we ignored this
one observation and supposed patients with non-response
to antidepressant after 6 weeks were only assigned to
increase the dose of their current antidepressant. Figure 2
shows a schematic for the RAD protocol. Response for
a given subject was defined as at least 50% improve-
ment over their initial SUMD (scale scores for depres-
sion) and not meeting the DSM-IV criteria for hypomania
or mania. Scores on the continuous symptom subscale
for depression (SUMD) range from 0 to 22, with higher
Table 1 Percentages of different mood stabilizers used in
RAD










Note that some patients received more than one mood stabilizer.
scores indicatingmore severe symptoms. Both SUMD and
SUMM (symptom subscale for mood elevation, SUMM
scores range from 0 to 16) are part of the modified clinical
monitoring form for mood disorders (Sachs et al. 2002).
Because subjects in RAD are potentially randomized
multiple times with randomizations occurring at cru-
cial points of the disease process, RAD is an example
of a Sequential Multiple Assignment Randomized Trial
(SMART) (Lavori and Dawson 2004; Murphy 2003). Data
collected in SMARTs can be used to efficiently estimate
and evaluate DTRs. In the next section, we formalize the
notion of an optimal DTR and introduce a regression-
based approach called Q-learning for estimating an opti-
mal DTR from a SMART.
Dynamic treatment regimes and Q-learning
The effective management of a chronic illness requires
ongoing personalized treatment (Wagner et al. 2001).
DTRs formalize clinical decision-making as sequence of
decision rules, one per treatment decision, that map
patient information to a recommended treatment. An
optimal DTR yields the optimal expected outcome when
applied to assign treatment to a population of inter-
est. One method for estimating an optimal DTR from
observational or randomized study data is Q-learning
(Murphy 2005; Schulte et al. 2014). Q-learning is an
approximate dynamic programming algorithm that can be
viewed as an extension of regression to multi-stage deci-
sion problems (Nahum-Shani et al. 2012b). As our focus
is the application of Q-learning to the RAD study within
the RCP pathway, we focus on data from a two-stage ran-
domized trial with a terminal continuous outcome; how-
ever, Q-learning applies in much more general settings
(Goldberg and Kosorok 2012; Laber et al. 2014; Moodie
et al. 2014; Schulte et al. 2014; Sutton and Barto 1998;
Watkins and Dayan 1992).
Q-learning estimates an optimal regime using backward
induction. For simplicity, we assume that the entire treat-
ment period contains two stages with a distal outcome
measured after completion of the second stage; treat-
ment decisions are made in the beginning of each stage.
Q-learning proceeds in two steps. In the first step, it esti-
mates an optimal treatment rule for the second stage of
treatment given patient-level data accumulated up to and
immediately preceding this second treatment assignment.
This information includes each patient’s baseline infor-
mation, stage 1 treatment assignment and intermediate,
i.e., proximal, outcomes measured during the course of
the first stage of treatment. These inputs to the second-
stage rule are treated as “independent variables” with no
attempt to infer what decision at stage 1 would be opti-
mal for a given patient. This first step is achieved by
regressing the distal outcome on patient information up
to decision stage 2 and manipulating the obtained analytic
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Figure 2 RAD design. At the beginning (stage 1), there are 365 patients in total. Eighty-five patients take Bupropion, 93 patients take Paroxetine,
and 187 patients take placebo. After 6 weeks, 104 patients’ information are lost. Only 78 patients are tracked with non-response at the end of stage
1. At stage 2, patients with non-response are assigned to secondary treatment intervention. Patients taking Bupropion or Paroxetine at stage 1 will
increase current doses. But patients taking placebo at stage 1 will be assigned Bupropion or Paroxetine.
expression to find for each patient which treatment at
stage 2 optimizes the expected distal outcome.
At the second step, Q-learning looks for treatment
assignment at stage 1 that would result in optimal distal
outcome, assuming that subsequent stage 2 treatment will
be determined by the rule constructed in step 1 of the
procedure. Such backward reasoning allowsQ-learning to
factor in future decisions when making treatment deci-
sions at earlier stages. This can be contrasted with a
myopic strategy that only looks at intermediate (proxi-
mal) outcomes of a current treatment assignment. For
example, treatments at stage 1 may lead to temporary alle-
viation of symptoms and therefore appear beneficial for
a patient; however, the long-term benefits may become
questionable after the later (e.g., second) stage decisions
are factored in.
Formal mathematical description of Q-learning
We now present formal mathematical description of Q-
learning. We assume that data available to estimate a DTR
are in the form of n independent, identically distributed
trajectories {(X1i,A1i,X2i,A2i,Yi)}ni=1, one for each subject
where: X1 ∈ Rp1 denotes baseline (pre-randomization)
subject information;A1 ∈ A1 denotes the first-stage treat-
ment assignment;X2 ∈ Rp2 denotes information collected
during the course of the first-stage treatment including
information dictating first-stage responder status; A2 ∈
A2 denotes the second-stage treatment assignment; and
Y ∈ R denotes a continuous outcome measured at the
end of the study coded so that lower values are better.
To match the RAD study, we assume that responders
are not re-randomized. In the RAD study, X1 contains a
subject’s age, race, gender, marital status, annual house-
hold income, employment status, education level, nine
different side effect measures, medical insurance type, as
well as baseline measures of bipolar type, clinical status
prior to depressive episode, scale scores for mood eleva-
tion (SUMM), and scale scores for depression (SUMD);
A1 denotes low-dose Bupropion, low-dose Paroxetine,
or placebo; X2 contains responder status at the end of
stage 1, as well as SUMM and SUMD at the end of
stage 1; A2 denotes either high-dose Bupropion or high-
dose Paroxetine; Y is SUMD measured at the end of
stage 2.
We use uppercase letters to denote random variables
and lowercase letters to denote instances of these ran-
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so that Hj denotes information available to the decision-
maker at stage j = 1, 2. For any random variable U , let
domU denote the set of possible values for U . A DTR is
a pair of functions π = (π1,π2) where πj : domHj →
domAj so that a patient presenting with Hj = hj at stage
j is assigned treatment πj(hj). For any hj ∈ domHj, let
Fj(hj) denote the set of feasible treatments for a patient
presenting at stage j with Hj = hj. In the RAD study
F1(h1) = {Bupropion, Paroxetine, and placebo}, for all h1.
At the second stage, responders are not re-randomized;







if A1 = Buproprion,{
high–dose Paroxetine
}
if A1 = Paroxetine,
{Buproprion, Parotexine} if A1 = placebo.
Let  = {π = (π1,π2), : πj(hj) ∈ Fj(hj) ,∀hj ∈ domHj}
denote the class of feasible DTRs (for a more formal dis-
cussion of feasibility see (Schulte et al. 2014)). An optimal
DTR, say πopt, satisfies EπoptY ≥ EπY for all π ∈ ,
where Eπ denotes expectation under the restriction that
Aj = πj(Hj). Define Q2(h2, a2) = E(Y |H2 = h2,A2 = a2)
and Q1(h1, a1) = E(mina2 Q2(H2, a2)|H1 = h1,A1 = a1).
The function Q2(h2, a2) measures the “quality” of assign-
ing treatment a2 to a patient presenting at stage 2 with
H2 = h2; the function Q1(h1, a1) measures the qual-
ity of assigning treatment a1 to a patient presenting at
stage 1 with H1 = h1 assuming optimal subsequent treat-
ment. It follows from dynamic programming (Bellman
1957) that πoptj (hj) = argminaj∈Fj(hj) Qj(hj, aj). In prac-
tice, dynamic programming cannot be applied because
the true Q-functions are not known; instead, estimation
of πopt must rely on the observed data. Q-learning is
an approximate dynamic programming algorithm which
mimics the dynamic programming solution by replacing
the conditional expectations required by dynamic pro-
gramming with regressionmodels fit to the observed data.
Let Qj(hj, aj; θj) denote a postulated working model for
Qj(hj, aj) indexed by unknown parameter θj.
In RAD, only patients who receive placebo as their first-
stage treatment and failed to respond are randomized at
the second stage. Thus, we only use these subjects to
estimate θ2. Let R denotes a subject first-stage responder
status so that R = 1 for responders and R = 0 for non-
responders. Define 1u to be equal to one if the condition
u is true and zero otherwise. A version of the Q-learning
algorithm that applies to data from RAD is:
Algorithm 1: Q-learning for RAD
(Q1) Compute θ̂2 = argminθ2
∑n
i=1{Yi − Q2(H2i,A2i;
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(Q3) Compute θ̂1 = argminθ1
∑n
i=1{Ŷi − Q1(H1i,A1i;










) = argminaj∈Fj(hj) Qj (hj, aj; θ̂j). To estimate πopt
using data from the RAD study, we posit linear models
for the Q-functions. For Q1(h1, a1), we posit a model of










)ᵀ, h1k , k = 0, 1, 2 are known
summary vectors of h1, and a1k , k = 1, 2 are dummy
variables coding two of the three possible treatments at
the first stage. For Q2(h2, a2), we posit a model of the






)ᵀ, h2k , k = 0, 1 are known summary vectors of
h2, and a2 is a dummy variable coding one of the two
possible treatments at the second stage.
Results
Analysis of STEP-BD
The Q-learning algorithm stated in the preceding section
assumes (i) complete data and (ii) working models for the
Q-functions. However, in RAD, as in most clinical trials, a
non-trivial amount of covariate and outcome information
aremissing. Furthermore, there is no strong theory to sug-
gest working models for the Q-functions. So we must use
the data to assist in the choice of these models. We com-
bine multiple imputation with stepwise variable selection
to estimate the Q-functions and subsequently the optimal
treatment regime.
Missing data
Figure 3 shows the proportions of missing values for the
variables under consideration in our analysis of the RAD
data. There is a significant amount of missing covariate
information at both stages; thus, discarding subjects with
missing information is inefficient and may introduce bias
(Little and Rubin 2002).
One approach in dealing with missing data is multi-
ple imputation (MI) (Rubin 2004). MI creates multiple
complete datasets and is thereby suited for conducting
a series of exploratory and secondary analyses including
estimation of an optimal treatment regime (Shortreed
et al. 2011). We use Bayesian MI to “fill in” the miss-
ing values which draws from the posterior predictive
distribution of the missing values given the observed
data (for details and underlying assumptions, see (Little
and Rubin 2002; Van Buuren 2012)). Implementation of
Bayesian MI requires specification of a prior and likeli-
hood for the observed data.We specify the joint likelihood
through the conditional distribution of each variable on
all other variables (for discussion of this approach, see
(Raghunathan et al. 2001; Van Buuren et al. 2006; Van
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Figure 3 Variable missingness. Variables with missing data are listed. The SUMMi and SUMDi denote continuous symptom subscales for
depression and mood elevation at ith stage. The Trti denotes current treatment at stage i. The responsei denotes patients’ clinical status at the end
of stage i. The SIDEj represents different side effects. PRONSET denotes patients’ prior to onset clinical status. EDUCATE, EMPLOY, MARSTAT, MEDINS,
and HINCOME are the indicators for patients’ education level, employment status, marriage status, medical insurance, and annual home income,
respectively.
Buuren 2007)). Thus, the likelihood is determined implic-
itly through a series of regression models, one for each
variable that contains missing information. For continu-
ous variables, we use predictive mean matching, and for
binary variables, we use logistic regression models. To
reduce variance, we use forward stepwise variable selec-
tion applied to the complete data to select predictors for
each conditional model. Flat improper priors were used
for all parameters. Imputations were carried out using the
freely available and open-source mice package with the
default settings (http://cran.r-project.org/web/packages/
mice/index.html). Complete R code implementing our
imputation model is provided in Additional file 1.
Using the procedure described above, we impute m
complete datasets. For a given choice of h1,k , k = 0, 1, 2
and h2,k , k = 0, 1, we can apply the Q-learning algo-
rithm to each imputed dataset to obtain estimated Q-
functions Qj
(
hj, aj; θ̂ ()j
)
, j = 1, 2,  = 1, . . . ,m. The
final estimated optimal decision rule is obtained as the








hj, aj; θ̂ ()j
)
.
Estimated optimal treatment regime and empirical results
We use a version of stepwise variable selection to opti-
mize the Bayesian information criteria (BIC); a complete
description of this procedure is given in the Appendix
section. The variables included in the model for
the second-stage Q-function are SIDE3, SUMD1, and
SUMM1. The variables included in the model for the
first-stage Q-function are AGE, PRONSET, SUMD0,
and SUMM0. Thus, the second-stage Q-functions has
the form Q2 (h2, a2; θ2) = βᵀ20h20 + a2βᵀ21h21, where
h20 = (1, SUMM1, SUMD1, SIDE3)ᵀ, h21 = (1, SUMM1,
SIDE3)ᵀ, and A2 is indicator variable for stage 2 treat-
ment coded so that A2 = 1 denotes high-dose Bupropion
and A2 = 0 denotes high-dose Paroxetine. The estimated
coefficients β̂20, β̂21 along with 90% bootstrap confidence
intervals are shown in Table 2. The table shows that the
main effect of A2 and interaction between second A2 and
SUMM1 is significant at the 90% level. The estimated opti-
mal decision rule is shown in Figure 4. As anticipated
by estimated second-stage Q-function, SUMM1 (mood
severity) and SIDE3 (sedation side effect) dictate treat-
ment selection; subjects with sedation side effects and low
mood severity are recommended to Bupropion, and all
others are recommended to Paroxetine.
The first-stageQ-function has the form Q1(h1, a1; θ1) =
β
ᵀ
10h10 + a11βᵀ11h11 + a12βᵀ12h12, where:
h10 = (1, AGE, SUMM0, SUMD0, PRONSET1, PRONSET2)ᵀ;
h11 = (1, SUMM0, PRONSET1, PRONSET2)ᵀ;
h12 = (1, SUMM0, PRONSET1, PRONSET2)ᵀ;
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Table 2 Point estimates and confidence intervals for the
coefficients indexing the second-stageQ-function
Variable Abbreviation Coefficient 90% confidence
estimate interval
SUMM1 SUMM1 0.18 (−0.14, 0.90)
SUMD1 SUMD1 0.50 (0.48, 0.83)
Side 3 SIDE3 −0.41 (−2.65, 0.42)
Intercept Int 2.21 (0.05, 2.00)
A2 × SUMM1 A2_SUMM1 0.77 (−0.16, 1.18)
A2 × Side 3 A2_SIDE3 1.82 (−1.05, 3.18)
A2 A2 −1.18 (−1.98, 0.00)
a11 = 1 if a1 = Bupriopion otherwise a11 = 0; a12 = 1
if a1 = Paroxetine otherwise a12 = 0; PRONSET1 = 1
if PRONSET = remission otherwise PRONSET1 = 0;
and PRONSET2 = 1 if PRONSET = manic or hypomanic
otherwise PRONSET2 = 0. The estimated coefficients
and 90% bootstrap intervals (corrected for non-regularity
as suggested by (Chakraborty et al. 2013)) are listed in
Table 3. Figure 5 shows the first-stage optimal decision
rule implied by the estimated Q-function. An interesting
feature of the first-stage decision rule is that subjects with
a (hypo)manic episode immediately preceding the current
major depressive episode are recommended to receive
placebo. This supports the hypothesis that subjects with
(hypo)manic episodes immediately preceding a major
depressive episode might not benefit from an adjuvant
antidepressant. Figure 5 also shows that among the sub-
jects experiencing remission or mixed/cycling before the
Figure 4 Estimated optimal second-stage decision rule. As
anticipated by the estimated second-stage Q-function, SUMM1 (scale
score for mood elevation) and SIDE3 (sedation side effect) are used to
dictate treatment.
Table 3 Point estimates and confidence intervals for the
coefficients indexing the first-stageQ-function
Variable Abbreviation Coefficient 90% Confidence
estimate interval
Age AGE 0.02 (−0.01, 0.04)
SUMM0 SUMM0 0.48 (0.35, 0.70)
SUMD0 SUMD0 0.20 (0.15, 0.36)
Prior episode 1 PRONSET1 −0.42 (−1.07, 0.42)
Prior episode 2 RPOSNET2 −0.86 (−1.49, -0.05)
Intercept Int 1.57 (−0.49, 2.50)
A11 × AGE A11_AGE 0.01 (−0.04, 0.07)
A11 × PRONSET1 A11_PRONSET1 0.66 (−0.80, 2.29)
A11 × PRONSET2 A11_PRONSET2 1.13 (−0.55, 2.82)
A11 A11 −1.55 (−4.07, 1.25)
A12 × AGE A12_AGE −0.03 (−0.08, 0.02)
A12 × PRONSET1 A12_PRONSET1 0.79 (−0.51, 1.92)
A12 × PRONSET2 A12_PRONSET2 1.62 (0.05, 2.90)
A12 A12 0.73 (−1.48, 3.08)
current major depressive episodes, Bupropion is recom-
mended to older patients and Paroxetine is recommended
to younger patients.
Recall that the optimal treatment regime minimizes the
expected depression score SUMD measured at week 12.
Thus, it is of interest to compare the estimated expected
12-week SUMD under the estimated optimal treatment
regime and other potential treatment regimes of inter-
est. Table 4 shows the estimated depression score under
the estimated regime and four static treatment regimes.
Estimates were computed using the inverse-probability-
weighted estimator (IPWE) (Zhang et al. 2013) and confi-
dence intervals using the non-parametric bootstrap. The
estimated optimal regime performs significantly better
at the 90% level than any fixed regime under consider-
ation. We note, however, that the confidence intervals
must be interpreted with caution as the IPWE is not a
smooth estimator which may cause the bootstrap to per-
form poorly (note that normal approximations do not hold
either without strong assumptions (Laber and Murphy
2011)).
Discussion
We estimated an optimal DTR for patients presenting
with bipolar depression using data from the RAD pathway
in the STEP-BD study. The estimated treatment regime
suggests the hypothesis that bipolar-depression patients
with (hypo)mania immediately preceding a major depres-
sive episode may do better to forgo adjunctive antide-
pressant treatment with either paroxetine or bupropion,
whereas the opposite is true for who were in remission or
experienced a mixed episode (manic episode with mixed
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Figure 5 Estimated optimal first-stage decision rule. Note that subjects with (hypo)manic episodes immediately preceding the current major
depressive episode are recommended to receive placebo.
features, according to DSM-V) before the current major
depressive episode. This is a novel finding, which has not
been explored so far. At present, there is a consensus that
antidepressants in the acute treatment of bipolar depres-
sion may be used when there is a history of previous
positive response to antidepressants, while they should
be avoided in patients with an acute bipolar depressive
episode with two or more concomitant core manic symp-
toms in the presence of psychomotor agitation, in patients
with a high number of previous episodes or with a his-
tory of rapid cycling and during depressive episodes with
mixed features (Pacchiarotti et al. 2013). Furthermore, the
use of antidepressants is discouraged if there is a history
of past mania, hypomania, or mixed episodes emerging
during antidepressant treatment (Pacchiarotti et al. 2013).
However, this consensus is mainly based on clinical wis-
dom than strong external evidence. In our study, the scale
scores for measuring symptoms of depression as well as
mania were available for baseline and stage 1 to model the
Q-functions but did not turn out to be helpful in building
an optimal DTR.
Table 4 Point estimates and confidence intervals for the
expected depression score SUMD at week 12 under static
regimes (first-line treatment, second-line treatment) and
estimated DTR
Regime (π1,π2) Estimated 90% Confidence
SUMD interval
Estimated DTR 2.13 (1.34, 2.86)
(Bupropion, high-dose Bupropion) 6.91 (6.27, 7.71)
(Paroxetine, high-dose Paroxetine) 8.25 (7.39, 9.07)
(placebo, high-dose Bupropion) 3.71 (3.38, 4.04)
(placebo, high-dose Paroxetine) 4.51 (4.10, 4.90)
So far, there are no reliable data on the differential effi-
cacy of paroxetine and bupropion in younger or older
adult patients with bipolar depression. In unipolar depres-
sion, a recent meta-analysis suggests that the efficacy of
antidepressants in general may be reduced in trials involv-
ing patients aged 65 years or older (Tedeschini et al. 2011).
Similarly, there have not been any reliable data suggest-
ing that patients with higher scores on mood elevation
scales do better on paroxetine than bupropion—and vice
versa (Pacchiarotti et al. 2013). What is well known on
the other hand is that Paroxetine 20 mg/day does not
seem to be associated with an increased risk of switch
into (hypo)mania in patients with bipolar depression, even
in monotherapy (McElroy et al. 2010). The data for our
analyses stem from a double-blind, randomized, placebo-
controlled trial (Sachs et al. 2007). Consequently, we do
not know whether in clinical practice not adding any
medication or intervention to a mood stabilizer is of com-
parable benefit for those who do best on placebo in our
analyses (Severus et al. 2012).
Conclusions
As mentioned in the introduction, estimation of an opti-
mal DTR is typically done as a secondary, exploratory
analysis and viewed as a method of generating hypothe-
ses for follow-up confirmatory experiments. The latter is
just about to start, using patients with bipolar depression
being openly treated within the SCP pathway of STEP-
BD using the same rating forms, in particular, the clinical
monitoring form for mood disorders.
Appendix
Variable selection
In order to estimate an optimal treatment regime using
Q-learning, we need to select which covariates to include
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the models for the Q-functions. Recall that the 12-week
depression SUMD score was used as the outcome (Y ).
We identified 24 potential predictors; these predictors are
listed in Table 5. We select a subset of these predictors
for each Q-function using stepwise variable selection to
minimize the Bayes information criterion (BIC) (Schwarz
et al. 1978) averaged over the multiply imputed datasets.
Let M2 denote a subset of predictors dictating the fea-
tures h2,k , k = 0, 1, and let θ̂ ()2 (M2) denote the coeffi-
cients obtained by applying step (Q1) of the Q-learning
algorithm with predictorsM2 to the th imputed dataset.
Define Ŷ ()i (M2), i = 1, . . . , n to be the predicted out-
comes computed in step (Q2) of the Q-learning algorithm
using the th imputed dataset and parameter θ̂ ()2 (M2).
LetM1 denotes a subset of predictors dictating h1,k , k =
0, 1, 2, and let θ̂ ()1 (M1,M2) denote the coefficients esti-
mated in step (Q3) of the Q-learning algorithm using
predictors M1 and predicted outcomes Ŷ ()i (M2), i =
1, . . . , n. In addition, let BIC() (M2) denote the BIC
for a second-stage model Q
(
h2, a2; θ̂ ()2 (M2)
)
calcu-
lated on the th imputed dataset. Similarly, and let
BIC()(M1,M2) denote the BIC for the first-stage model
Q
(
h1, a1; θ̂ ()1 (M1,M2)
)
calculated on the th imputed
dataset. This procedure that we use to construct models
for the Q-learning algorithm is:
Table 5 Candidate predictors for regressionmodels inQ-learning
Variable Description Abbreviation Type Values (range or level) Mean (SD) or frequency (%)
Age Age at entry (years) AGE Numerical 18–77 40.59 (11.74)
Race Race RACE Binary White or Causasian, non-White 90.4%, 9.6%
Gender Gender GENDER Trinary Male, female, transgender 43%, 56%, 1%
Marriage Marital status MARSTAT Trinary Never married, married, 35.6%, 33.8%, 30.6%
separated
Household Income Annual household income HINCOME Binary < 40, ≥ 40 58.5%, 41.5%
(×$1000)
Employment Employment status EMPLOY Binary Employed, unemployed 46.9%, 53.1%
Education Education level EDUCATE Binary College or below, technical 53%, 47%
school or above
Insurance Indicator of medical insurance MEDINS Binary Yes, no 72.8%, 27.2%
Bipolar Type Bipolar type at entry BITYPE Binary Type I, type II 70.4%, 29.6%
Prior Episode Clinical episode immediately PRONSET Trinary Remission, (hypo)manic, 45.9%, 33.2%, 20.9%
preceding current depressive mixed
episode
SUMD0 Scaled depression at entry SUMD0 Numerical 0.75–18 7.47 (2.30)
SUMD1a Scaled depression at the end SUMD1 Numerical 0–14 4.49 (3.07)
of stage 1
SUMM0 Scaled mood elevation at entry SUMM0 Numerical 0–7 1.19 (1.09)
SUMM1a Scaled mood elevation at the SUMM1 Numerical 0–6.75 0.95 (1.30)
end of stage 1
Treatment 1a Treatment received at stage 1 Trt1 Trinary Bupropion, Paroxetine, 23.3%, 25.5%, 51.2%
placebo
Side 1 Tremor SIDE1 Binary Yes, no 26.9%, 73.1%
Side 2 Dry mouth SIDE2 Binary Yes, no 21.1%, 78.9%
Side 3 Sedation SIDE3 Binary Yes, no 17.1%, 82.9%
Side 4 Constipation SIDE4 Binary Yes, no 5.7%, 94.3%
Side 5 Diarrhea SIDE5 Binary Yes, no 12%, 88%
Side 6 Headache SIDE6 Binary Yes, no 13.7%, 86.3%
Side 7 Poor memory SIDE7 Binary Yes, no 14.3%, 85.7%
Side 8 Sexual dysfunction SIDE8 Binary Yes, no 9.7%, 90.3%
Side 9 Increased appetite SIDE9 Binary Yes, no 12.6%, 87.4%
aThose that are only available for the second-stage regression model.
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